ATE357255T1 - Plazenta-wachstumsfaktor als target für die behandlung von osteoporose - Google Patents

Plazenta-wachstumsfaktor als target für die behandlung von osteoporose

Info

Publication number
ATE357255T1
ATE357255T1 AT03761596T AT03761596T ATE357255T1 AT E357255 T1 ATE357255 T1 AT E357255T1 AT 03761596 T AT03761596 T AT 03761596T AT 03761596 T AT03761596 T AT 03761596T AT E357255 T1 ATE357255 T1 AT E357255T1
Authority
AT
Austria
Prior art keywords
treatment
growth factor
osteoporosis
target
bone
Prior art date
Application number
AT03761596T
Other languages
English (en)
Inventor
Peter Carmeliet
Desire Collen
Roger Bouillon
Gertrudis Carmeliet
Original Assignee
Vlaams Interuniv Inst Biotech
Leuven K U Res & Dev
D Collen Res Foundation Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Interuniv Inst Biotech, Leuven K U Res & Dev, D Collen Res Foundation Vzw filed Critical Vlaams Interuniv Inst Biotech
Application granted granted Critical
Publication of ATE357255T1 publication Critical patent/ATE357255T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03761596T 2002-06-28 2003-06-27 Plazenta-wachstumsfaktor als target für die behandlung von osteoporose ATE357255T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02077591 2002-06-28

Publications (1)

Publication Number Publication Date
ATE357255T1 true ATE357255T1 (de) 2007-04-15

Family

ID=29797249

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03761596T ATE357255T1 (de) 2002-06-28 2003-06-27 Plazenta-wachstumsfaktor als target für die behandlung von osteoporose

Country Status (8)

Country Link
US (1) US7357929B2 (de)
EP (2) EP1517704A1 (de)
JP (1) JP2005535634A (de)
AT (1) ATE357255T1 (de)
AU (2) AU2003251728A1 (de)
CA (1) CA2491053A1 (de)
DE (1) DE60312684T2 (de)
WO (2) WO2004002524A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1297016B1 (de) * 2000-05-12 2006-03-22 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)
PL1614731T3 (pl) 2004-07-05 2009-02-27 3M Innovative Properties Co Pierwsza powłoka z PTFE do przedmiotów metalowych
CN101184776B (zh) 2005-03-24 2013-04-24 斯路姆基因公司 新型抗胎盘生长因子抗体
CN101534865A (zh) * 2005-10-19 2009-09-16 Ibc药品公司 生物活性装配体的制备方法及其用途
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2638823A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
EP2785739B1 (de) 2011-12-01 2017-03-15 ThromboGenics N.V. Verbesserung eines augendrucksenkungsergebnisses
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
US9149471B2 (en) * 2013-09-30 2015-10-06 National University Corporation Tokyo University Of Agriculture And Technology Therapeutic agent for osteoporosis
US20190031762A1 (en) 2016-03-10 2019-01-31 Thrombogenics Nv Posterior ocular fibrosis inhibition by antagonizing placental growth factor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69322860T2 (de) 1992-04-03 1999-07-01 Genentech, Inc., South San Francisco, Calif. Antikörper gegen alpha v beta 3 integrin
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5670057A (en) 1995-04-28 1997-09-23 Baxter International Inc. Apparatus and method for automatically performing peritoneal equilibration tests
JP2001086982A (ja) * 1999-07-16 2001-04-03 Shunpei Niida 骨吸収調節薬
EP1297016B1 (de) * 2000-05-12 2006-03-22 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)
WO2003000183A2 (en) 2001-06-20 2003-01-03 Imclone Systems Incorporated Method of treating atherosclerosis and other inflammatory diseases

Also Published As

Publication number Publication date
AU2003251728A1 (en) 2004-01-19
US7357929B2 (en) 2008-04-15
EP1517703B1 (de) 2007-03-21
AU2003251729A1 (en) 2004-01-19
US20050175609A1 (en) 2005-08-11
AU2003251728A8 (en) 2004-01-19
CA2491053A1 (en) 2004-01-08
EP1517703A1 (de) 2005-03-30
DE60312684T2 (de) 2007-12-06
JP2005535634A (ja) 2005-11-24
WO2004002524A1 (en) 2004-01-08
AU2003251729A8 (en) 2004-01-19
WO2004002525A1 (en) 2004-01-08
DE60312684D1 (de) 2007-05-03
EP1517704A1 (de) 2005-03-30

Similar Documents

Publication Publication Date Title
ATE538650T1 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
EP1606286A4 (de) Benzodiazepinspirohydantoine als cgrp-rezeptorantagonisten
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
ATE353640T1 (de) Antagoniste zur behandlung von cd11/cd18 adhäsionsrezeptor-vermittelten krankheiten
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
DE602004013563D1 (de) Rantagonisten
SE0301010D0 (sv) Novel compounds
ATE435210T1 (de) Tetrahydroisochinolylacetamidderivate zur verwendung als orexinrezeptorantagonisten
MXPA04003858A (es) Antagonistas de mch para el tratamiento de obesidad.
SE0301009D0 (sv) Novel compounds
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
ATE433447T1 (de) Pyrimiidinverbindungen
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
ATE357255T1 (de) Plazenta-wachstumsfaktor als target für die behandlung von osteoporose
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
BR0211761A (pt) depsipeptìdeos e processos para preparar os mesmos
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
DE60232880D1 (de) Gpe-analoga und peptidomimetika
TW200724140A (en) Hydantoin compounds
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DE60135158D1 (de) Antagonisten des ige-rezeptors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties